Allarity Therapeutics Files for $100 Million SPAC IPO

Key Facts

1Allarity Therapeutics announced that its newly formed SPAC, Allarity Acquisition Corp., filed a registration statement for a $100 million IPO.

2The SPAC aims to list its units on the Nasdaq stock exchange under the ticker symbol ALLNU.

3The company stated that the offering does not affect its previously reported financial runway through summer 2028.

In a move reflecting a strategic shift toward diversifying funding sources within the biotech sector, Allarity Therapeutics has filed a registration statement for a $100 million IPO of its newly formed SPAC, Allarity Acquisition Corp. According to reports, the special purpose acquisition company intends to list its units on the Nasdaq exchange under the ticker symbol ALLNU. This initiative serves as a capital allocation strategy to sponsor future business combinations while the parent firm remains focused on oncology treatments.

The company emphasized that this offering will not impact its previously reported financial runway, which remains secured through the summer of 2028. Per market data, the parent company's move is viewed as a strategic effort to create new capital channels without depleting existing cash reserves, a typical maneuver for mid-cap firms seeking expansion through corporate actions.

According to market data, ALLR closed at $1.25 on September 10, 2026, while NDAQ closed at $92.01 on the same date. Investors will be watching for the formal commencement of the IPO and the subsequent listing of ALLNU units on the Nasdaq, as the company maintains its operational focus through its established financial stability.